Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to read, understand, and sign a consent form agreeing to the study's requirements
- People aged between 35 and 65 years old
- Women who are either unable to become pregnant (for example, due to having had a tubal ligation, hysterectomy, or having gone through menopause with no period for at least 12 months), or women who are able to become pregnant but are confirmed not currently pregnant and willing to use an approved contraception method during the study
- Men who are willing to use an approved contraception method during the study
- People who are willing to avoid drinking alcohol for the entire time they are taking the study medication
- People with Secondary Progressive Multiple Sclerosis (SPMS) who score between 3.5 and 6.5 on a disability scale used to measure MS progression (confirm exact scoring requirements with trial site)
Who may not be able to join:
- People who have a history of a neurological condition other than migraine or MS
- People whose routine blood test results show certain abnormalities, such as reduced kidney function, elevated liver enzymes or bilirubin, abnormal blood clotting time, or a low platelet count
- People who have used certain medications in the past 6 months or currently, including immune-suppressing or immune-modifying drugs, a treatment called alemtuzumab or stem cell therapy, medications that affect the central nervous system (such as opioid painkillers, sleeping pills, barbiturates, antihistamines, or antipsychotics), certain other drugs that affect how the body processes medications, oral contraceptives, blood thinners or anti-clotting medications (other than low-dose aspirin), or thyroid hormone medication (levothyroxine)
- People who are currently breastfeeding
- People with any significant medical condition that the trial doctor believes could affect their safety or ability to follow the study procedures
- People with a history of certain chronic conditions affecting the blood, liver, kidneys, or hormonal system that could affect the reliability of the study results, as assessed by the principal investigator
- People who are unwilling or unable to follow the study procedures as outlined
- People who are not in a position to make their own legal or medical decisions
- People who have a known allergy or sensitivity to XBD173 or any of its ingredients
- People with myasthenia gravis, or with certain rare conditions affecting the body's ability to process specific sugars (such as glucose-galactose malabsorption or lactose deficiency), which may make the study drug etifoxine unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Paul Matthews, PhD, Imperial College London
Phone: 07801140800
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Monocyte phenotye - Tissue necrosis factor-α; Monocyte phenotye - Interferon-γ; Monocyte phenotype - Interleukins- 1β; Monocyte phenotype - Interleukins- 16; Monocyte phenotype - Interleukins- 17; Monocyte phenotype - Interleukins- 23; Immunomodulatory factor -Transforming growth factor-β; Immunomodulatory factor - Interleukins -4; Immunomodulatory factor - Interleukins - 10; Relative proportions of WBC subsets
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.